- Novo Nordisk signed a licensing deal valued at more than $1 billion.
- The deal lands days after Novo's capital-markets day disappointed investors seeking clarity on the company's next phase.
- The licensing agreement sent the Swedish counterparty's shares sharply higher.
Quotes
“Just days after a capital-markets day left investors wondering what's next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion.”